3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
39
Leukemia, Myeloid, Acute
35
Myelodysplastic Syndromes
33
Multiple Myeloma
30
Lymphoma, Non-Hodgkin
29
Hodgkin Disease
28
Graft vs Host Disease
26
Leukemia, Lymphocytic, Chronic, B-Cell
25
Lymphoma
24
Leukemia
24
Hematologic Neoplasms
20
Neoplasms
18
Lymphoma, Mantle-Cell
18
Sarcoma
17
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
17
Breast Neoplasms
17
Tuberous Sclerosis
15
Myeloproliferative Disorders
15
Lymphoma, Large B-Cell, Diffuse
15
Lymphoma, Follicular
14
Burkitt Lymphoma
14
Waldenstrom Macroglobulinemia
13
Lymphoma, B-Cell, Marginal Zone
13
Recurrence
12
Neoplasm Metastasis
12
Carcinoma, Non-Small-Cell Lung
12
Prostatic Neoplasms
11
Primary Myelofibrosis
11
Melanoma
11
Leukemia, Myelomonocytic, Chronic
11
Interventions
pembrolizumab
162
Carboplatin
144
Paclitaxel
125
Cyclophosphamide
93
130-nm albumin-bound paclitaxel
66
Capecitabine
63
Gemcitabine
54
Doxorubicin
49
Albumin-Bound Paclitaxel
45
Taxes
42
atezolizumab
40
Cisplatin
38
Nivolumab
34
sacituzumab govitecan
32
olaparib
32
Epirubicin
32
Docetaxel
28
eribulin
27
Specimen Handling
26
Bevacizumab
26
durvalumab
25
camrelizumab
23
Drug Therapy
22
Biopsy
22
Magnetic Resonance Spectroscopy
21
toripalimab
18
Radiotherapy
17
spartalizumab
16
Everolimus
15
fludarabine
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Triple Negative Breast Neoplasms
×
Sirolimus
×
Clear all
NCT03805399
2022-08-10
FUTURE
Fudan University
Phase 1/2
Unknown
140 enrolled